|
FY2025
12 months to Dec 31, 2025
|
|
|---|---|
| Research and development ("R&D") | |
| General and administrative ("G&A") | |
| TOTAL OPERATING EXPENSES: | |
| OTHER INCOME AND EXPENSES | |
| Finance income | |
| Foreign exchange gain | |
| NET LOSS BEFORE INCOME TAXES | |
| Income tax expense | |
| NET LOSS FOR THE YEAR | |
| OTHER COMPREHENSIVE LOSS | |
| Item that may be reclassified to net loss | |
| Foreign currency translation adjustment | |
| TOTAL COMPREHENSIVE LOSS | |
| Basic loss per Common Share (in dollars per share) | |
| Diluted loss per Common Share (in dollars per share) | |
| Basic loss per Pre-Funded Warrant (in dollars per share) | |
| Diluted loss per Pre-Funded Warrant (in dollars per share) | |
| Weighted average number of Common Shares, basic (in shares) | |
| Weighted average number of Common Shares, diluted (in shares) |
Loading...
